Search Within

Andrew D Seidman

  1. "Mark Robson"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (12)
Groups
  1. Breast Medicine Service (26)
  2. Department of Medicine (26)
  3. Population Sciences Research Program (26)
  4. Solid Tumor Oncology Division (26)
  5. Survivorship Research (26)
  6. Epidemiology and Biostatistics (22)

More Groups

People
  1. Mark Robson (26)
  2. Chau Dang (17)
  3. Clifford Hudis (14)
  4. Gabriella D'Andrea-Carlino (13)
  5. Larry Norton (13)
  6. Monica Fornier (13)

More People

Years
  1. 2024 (3)
  2. 2023 (2)
  3. 2022 (2)
  4. 2021 (1)
  5. 2020 (1)
  6. 2018 (2)

More Years

Publications
  1. Journal of Clinical Oncology (7)
  2. Breast Cancer Research and Treatment (4)
  3. Clinical Cancer Research (3)
  4. Cancer Research (2)
  5. European Journal of Cancer (2)
  6. International Journal of Radiation Oncology, Biology, Physics (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. American Association for Cancer Research (5)
  3. Elsevier Inc. (4)
  4. Springer (4)
  5. Nature Publishing Group (2)
  6. Oxford University Press (2)

More Publishers

Results (26)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients
    Journal Article

    Bao, T.; Seidman, A. D.; Piulson, L.; Vertosick, E.; Chen, X.; Vickers, A. J.; Blinder, V. S.; Zhi, W. I.; Li, Q.; Vahdat, L. T.; more...
    European Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Integration of multi-modality treatment planning for early stage breast cancer (BC) into Watson for Oncology, a Decision Support System: Seeing the forest and the trees
    Meeting Abstract

    Seidman, A. D.; Pilewskie, M. L.; Robson, M. E.; Kelvin, J. F.; Zauderer, M. G.; Epstein, A. S.; Kris, M. G.; Fu, J.; Keesing, J.; Caroline, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Morris, P. G.; Lake, D. E.; D'Andrea, G. M.; Dickler, M. N.; Gilewski, T. A.; Dang, C. T.; McArthur, H. L.; Bromberg, J. F.; Goldfarb, S. B.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Journal Article

    Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer
    Journal Article

    Traina, T. A.; Rugo, H. S.; Caravelli, J. F.; Patil, S.; Yeh, B.; Melisko, M. E.; Park, J. W.; Geneus, S.; Paulson, M.; Grothusen, J.; more...
    Journal of Clinical Oncology (2010)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT)
    Meeting Abstract

    Conlin, A. K.; D'Andrea, G.; Hudis, C. A.; Robson, M. E.; Drullinsky, P.; Theodoulou, M.; Lis, E.; Kang, T. Y.; Peereboom, D. M.; Seidman, A. D.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Increased dose density is feasible: A pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Journal Article

    Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C.; Panageas, K. S.; Atienza, M.; Norton, L.; more...
    Clinical Cancer Research (2007)

    Fulltext@MSK | Save
  • Mature cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Fornier, M.; Sugarman, S.; Troso, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; George, R.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save